Back

Hanmi completes Phase 2 core treatment for once-weekly efpeglucagon

Verifying
  • Hanmi Pharmaceutical completed the global Phase 2 core treatment period for efpeglucagon.
  • Efpeglucagon received FDA breakthrough therapy designation in February.
  • Hanmi will present trial findings at ESPE 2026 on the 8th-10th in Marseille.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Hanmi completes Phase 2 core treatment for once-weekly efpeglucagon - CoinPost Terminal